# Janux Therapeutics, Inc.: financial statements, quarterly

JANX · Nasdaq · CIK 1817713 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/janx.md) · [Financials](/companies/janx/financials.md) · [Filings](/companies/janx/filings.md) · [Insiders](/companies/janx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/janx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.5](/filings/0000950170-24-122370.md) | [2.5 d](/filings/0001193125-26-076918.md) | [1.3](/filings/0000950170-25-067083.md) | [8.9](/filings/0000950170-25-105069.md) | [0.4](/filings/0001193125-25-269799.md) | [0.0 d](/filings/0001193125-26-076918.md) | [0.0](/filings/0001193125-26-212146.md) | [0.0](/filings/0001193125-26-338078.md) | [10.0](/filings/0001193125-25-269799.md) | [0.0 d](/filings/0001193125-26-076918.md) | [3.7](/filings/0001193125-26-212146.md) | [10.3](/filings/0001193125-26-338078.md) |
| Research and development | $m | [11.9](/filings/0000950170-24-122370.md) | [12.2 d](/filings/0001193125-26-076918.md) | [14.1](/filings/0000950170-25-067083.md) | [14.9](/filings/0000950170-25-105069.md) | [18.6](/filings/0001193125-25-269799.md) | [20.8 d](/filings/0001193125-26-076918.md) | [25.1](/filings/0001193125-26-212146.md) | [34.7](/filings/0001193125-26-338078.md) | [34.6](/filings/0001193125-25-269799.md) | [31.5 d](/filings/0001193125-26-076918.md) | [26.8](/filings/0001193125-26-212146.md) | [31.0](/filings/0001193125-26-338078.md) |
| Operating income | $m | [(15.8)](/filings/0000950170-24-122370.md) | [(16.1) d](/filings/0001193125-26-076918.md) | [(20.2)](/filings/0000950170-25-067083.md) | [(13.8)](/filings/0000950170-25-105069.md) | [(35.8)](/filings/0001193125-25-269799.md) | [(29.0) d](/filings/0001193125-26-076918.md) | [(34.9)](/filings/0001193125-26-212146.md) | [(45.1)](/filings/0001193125-26-338078.md) | [(35.3)](/filings/0001193125-25-269799.md) | [(42.4) d](/filings/0001193125-26-076918.md) | [(34.2)](/filings/0001193125-26-212146.md) | [(31.7)](/filings/0001193125-26-338078.md) |
| Net income | $m | [(11.6)](/filings/0000950170-24-122370.md) | [(11.8) d](/filings/0001193125-26-076918.md) | [(14.8)](/filings/0000950170-25-067083.md) | [(6.0)](/filings/0000950170-25-105069.md) | [(28.1)](/filings/0001193125-25-269799.md) | [(20.2) d](/filings/0001193125-26-076918.md) | [(23.5)](/filings/0001193125-26-212146.md) | [(33.9)](/filings/0001193125-26-338078.md) | [(24.3)](/filings/0001193125-25-269799.md) | [(31.9) d](/filings/0001193125-26-076918.md) | [(24.4)](/filings/0001193125-26-212146.md) | [(22.0)](/filings/0001193125-26-338078.md) |
| Diluted EPS | $ per share | [(0.25)](/filings/0000950170-24-122370.md) | not reported | [(0.30)](/filings/0000950170-25-067083.md) | [(0.11)](/filings/0000950170-25-105069.md) | [(0.51)](/filings/0001193125-25-269799.md) | not reported | [(0.38)](/filings/0001193125-26-212146.md) | [(0.55)](/filings/0001193125-26-338078.md) | [(0.39)](/filings/0001193125-25-269799.md) | not reported | [(0.39)](/filings/0001193125-26-212146.md) | [(0.35)](/filings/0001193125-26-338078.md) |
| Basic EPS | $ per share | [(0.25)](/filings/0000950170-24-122370.md) | not reported | [(0.30)](/filings/0000950170-25-067083.md) | [(0.11)](/filings/0000950170-25-105069.md) | [(0.51)](/filings/0001193125-25-269799.md) | not reported | [(0.38)](/filings/0001193125-26-212146.md) | [(0.55)](/filings/0001193125-26-338078.md) | [(0.39)](/filings/0001193125-25-269799.md) | not reported | [(0.39)](/filings/0001193125-26-212146.md) | [(0.35)](/filings/0001193125-26-338078.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [17.2](/filings/0000950170-23-060288.md) | [19.2](/filings/0000950170-25-029177.md) | [213](/filings/0000950170-24-054966.md) | [14.7](/filings/0000950170-24-092857.md) | [26.8](/filings/0000950170-24-122370.md) | [431](/filings/0001193125-26-076918.md) | [73.7](/filings/0000950170-25-067083.md) | [52.4](/filings/0000950170-25-105069.md) | [48.4](/filings/0001193125-25-269799.md) | [52.3](/filings/0001193125-26-338078.md) | [51.8](/filings/0001193125-26-212146.md) | [27.8](/filings/0001193125-26-338078.md) |
| Current assets | $m | [355](/filings/0000950170-23-060288.md) | [349](/filings/0000950170-25-029177.md) | [659](/filings/0000950170-24-054966.md) | [662](/filings/0000950170-24-092857.md) | [666](/filings/0000950170-24-122370.md) | [1,034](/filings/0001193125-26-076918.md) | [1,023](/filings/0000950170-25-067083.md) | [1,006](/filings/0000950170-25-105069.md) | [998](/filings/0001193125-25-269799.md) | [976](/filings/0001193125-26-338078.md) | [1,002](/filings/0001193125-26-212146.md) | [983](/filings/0001193125-26-338078.md) |
| Total assets | $m | [387](/filings/0000950170-23-060288.md) | [380](/filings/0000950170-25-029177.md) | [689](/filings/0000950170-24-054966.md) | [691](/filings/0000950170-24-092857.md) | [695](/filings/0000950170-24-122370.md) | [1,062](/filings/0001193125-26-076918.md) | [1,051](/filings/0000950170-25-067083.md) | [1,032](/filings/0000950170-25-105069.md) | [1,025](/filings/0001193125-25-269799.md) | [1,002](/filings/0001193125-26-338078.md) | [1,028](/filings/0001193125-26-212146.md) | [1,008](/filings/0001193125-26-338078.md) |
| Current liabilities | $m | [14.5](/filings/0000950170-23-060288.md) | [13.0](/filings/0000950170-25-029177.md) | [10.6](/filings/0000950170-24-054966.md) | [11.5](/filings/0000950170-24-092857.md) | [17.2](/filings/0000950170-24-122370.md) | [17.5](/filings/0001193125-26-076918.md) | [17.5](/filings/0000950170-25-067083.md) | [21.4](/filings/0000950170-25-105069.md) | [27.8](/filings/0001193125-25-269799.md) | [25.0](/filings/0001193125-26-338078.md) | [58.9](/filings/0001193125-26-212146.md) | [60.2](/filings/0001193125-26-338078.md) |
| Total liabilities | $m | [37.9](/filings/0000950170-23-060288.md) | [36.1](/filings/0000950170-25-029177.md) | [33.2](/filings/0000950170-24-054966.md) | [33.7](/filings/0000950170-24-092857.md) | [38.9](/filings/0000950170-24-122370.md) | [38.7](/filings/0001193125-26-076918.md) | [38.3](/filings/0000950170-25-067083.md) | [41.7](/filings/0000950170-25-105069.md) | [48.2](/filings/0001193125-25-269799.md) | [44.7](/filings/0001193125-26-338078.md) | [86.7](/filings/0001193125-26-212146.md) | [79.7](/filings/0001193125-26-338078.md) |
| Shareholders' equity | $m | [349](/filings/0000950170-24-122370.md) | [344](/filings/0001193125-26-076918.md) | [656](/filings/0000950170-25-105069.md) | [658](/filings/0001193125-25-269799.md) | [656](/filings/0001193125-25-269799.md) | [1,023](/filings/0001193125-26-338078.md) | [1,012](/filings/0001193125-26-338078.md) | [991](/filings/0001193125-26-338078.md) | [977](/filings/0001193125-25-269799.md) | [957](/filings/0001193125-26-338078.md) | [942](/filings/0001193125-26-338078.md) | [928](/filings/0001193125-26-338078.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.7) d](/filings/0000950170-24-122370.md) | [(9.9) d](/filings/0001193125-26-076918.md) | [(14.8)](/filings/0000950170-25-067083.md) | [(10.0) d](/filings/0000950170-25-105069.md) | [(2.2) d](/filings/0001193125-25-269799.md) | [(16.7) d](/filings/0001193125-26-076918.md) | [(17.0)](/filings/0001193125-26-212146.md) | [(23.8) d](/filings/0001193125-26-338078.md) | [(12.9) d](/filings/0001193125-25-269799.md) | [(28.5) d](/filings/0001193125-26-076918.md) | [(12.3)](/filings/0001193125-26-212146.md) | [12.5 d](/filings/0001193125-26-338078.md) |
| Capital expenditure | $m | [0.5 d](/filings/0000950170-24-122370.md) | [0.5 d](/filings/0001193125-26-076918.md) | [0.2](/filings/0000950170-25-067083.md) | [0.1 d](/filings/0000950170-25-105069.md) | [0.0 d](/filings/0001193125-25-269799.md) | [0.0 d](/filings/0001193125-26-076918.md) | [0.4](/filings/0001193125-26-212146.md) | [0.5 d](/filings/0001193125-26-338078.md) | [0.1 d](/filings/0001193125-25-269799.md) | [0.1 d](/filings/0001193125-26-076918.md) | [0.3](/filings/0001193125-26-212146.md) | [0.2 d](/filings/0001193125-26-338078.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.5](/filings/0000950170-23-060288.md) | [41.8](/filings/0000950170-24-054966.md) | [41.8](/filings/0000950170-24-092857.md) | [45.7](/filings/0000950170-24-122370.md) | [49.0](/filings/0000950170-25-067083.md) | [54.5](/filings/0000950170-25-105069.md) | [54.6](/filings/0001193125-25-269799.md) | [61.8](/filings/0001193125-26-212146.md) | [61.9](/filings/0001193125-26-338078.md) | [62.0](/filings/0001193125-25-269799.md) | [62.7](/filings/0001193125-26-212146.md) | [62.9](/filings/0001193125-26-338078.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,136,773 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338078.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.